Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 2/20 | 0.43 |
| ▸ | DTYMK | P23919 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30854767 | 1.00 | VCAM1 (0.43) | VCAM1DTYMKPOLBTSHRTHRB | |
| SCHEMBL8576640 | 0.94 | VCAM1 (0.43) | VCAM1DTYMKPOLBTSHRTHRB | |
| SCHEMBL6573522 | 0.87 | MAPT (0.44) | VCAM1POLBTHRBALDH1A1MAPT | |
| SCHEMBL15573015 | 0.85 | DTYMK (0.40) | VCAM1DTYMKPOLBTSHRALDH1A1 | |
| SCHEMBL3583323 | 0.84 | VCAM1 (0.56) | VCAM1POLBTHRBALDH1A1TDP1 | |
| SCHEMBL15573830 | 0.82 | VCAM1 (0.44) | VCAM1POLBTHRB | |
| SCHEMBL23850658 | 0.80 | VCAM1 (0.49) | VCAM1THRBALDH1A1MAPTLMNA | |
| SCHEMBL29550827 | 0.80 | VCAM1 (0.49) | VCAM1THRBALDH1A1MAPTLMNA | |
| SCHEMBL405684 | 0.80 | DTYMK (0.51) | DTYMKTSHRALDH1A1MAPTLMNA | |
| SCHEMBL13948939 | 0.79 | DTYMK (0.50) | VCAM1DTYMKTSHRALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112218627-B | Prodrugs and their medical use | 康维尔特制药有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20210205299-A1 | PRODRUGS AND MEDICAL USES THEREOF | CONVERT PHARMACEUTICALS (BE) | 2021-07-08 | — | — | US | disclosed |
| EP-3801481-A1 | PRODRUGS AND MEDICAL USES THEREOF | Convert Pharmaceuticals SA (BE) | 2021-04-14 | — | — | EP | disclosed |
| CN-112218627-A | Prodrugs and their use in medicine | 康维尔特制药有限公司 | 2021-01-12 | — | — | CN | disclosed |
| EP-2888227-B1 | NOVEL PRODRUGS AND METHODS OF USE THEREOF | Convert Pharmaceuticals SA (BE) | 2020-07-29 | — | — | EP | disclosed |
| US-20190153002-A1 | Novel Prodrugs And Methods Of Use Thereof | Convert Pharmaceuticals SA (BE) | 2019-05-23 | — | — | US | disclosed |
| US-10202408-B2 | Prodrugs and methods of use thereof | HEALTH INNOVATION VENTURES B.V. (NL) | 2019-02-12 | — | — | US | disclosed |
| US-20180148463-A1 | Novel Prodrugs And Methods Of Use Thereof | Convert Pharmaceuticals SA (BE) | 2018-05-31 | — | — | US | disclosed |
| US-9873710-B2 | Prodrugs and methods of use thereof | HEALTH INNOVATION VENTURES B.V. (NL) | 2018-01-23 | — | — | US | disclosed |
| US-20170044191-A1 | Novel Prodrugs And Methods Of Use Thereof | Convert Pharmaceuticals SA (BE) | 2017-02-16 | — | — | US | disclosed |
| EP-2888227-A1 | NOVEL PRODRUGS AND METHODS OF USE THEREOF | Auckland Uniservices Limited (NZ) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014031012-A1 | NOVEL PRODRUGS AND METHODS OF USE THEREOF | AUCKLAND UNISERVICES LIMITED (NZ) | 2014-02-27 | — | — | WO | disclosed |
| CN-1902159-B | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNISERVICES LTD | 2010-06-09 | — | — | CN | disclosed |
| US-20100010094-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-01-14 | — | — | US | disclosed |
| US-7629332-B2 | Nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-12-08 | — | — | US | disclosed |
| US-20070032455-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNIVERVICES LIMITED (NZ) | 2007-02-08 | — | — | US | disclosed |
| CN-1902159-A | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNISERVICES LTD (NZ) | 2007-01-24 | — | — | CN | disclosed |
| EP-1680394-A4 | NOVEL NITROPHENYL MUSTARD AND NITROPHENYLAZIRIDINE ALCOHOLS AND THEIR CORRESPONDING PHOSPHATES AND THEIR USE AS TARGETED CYTOTOXIC AGENTS | AUCKLAND UNISERVICES LTD (NZ) | 2006-10-11 | — | — | EP | disclosed |
| EP-1680394-A1 | NOVEL NITROPHENYL MUSTARD AND NITROPHENYLAZIRIDINE ALCOHOLS AND THEIR CORRESPONDING PHOSPHATES AND THEIR USE AS TARGETED CYTOTOXIC AGENTS | Auckland Uniservices Limited (NZ) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005042471-A1 | NOVEL NITROPHENYL MUSTARD AND NITROPHENYLAZIRIDINE ALCOHOLS AND THEIR CORRESPONDING PHOSPHATES AND THEIR USE AS TARGETED CYTOTOXIC AGENTS | AUCKLAND UNISERVICES LIMITED (NZ) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148463-A1 | Novel Prodrugs And Methods Of Use Thereof | AKR1C3, AKR1C2, AKR1B1 | VCAM1 3435/4885DTYMK 262/4885POLB 952/4885 |
| US-20190153002-A1 | Novel Prodrugs And Methods Of Use Thereof | AKR1C3, AKR1C2, AKR1B1 | VCAM1 3435/4885DTYMK 262/4885POLB 952/4885 |
| US-20210205299-A1 | PRODRUGS AND MEDICAL USES THEREOF | GLS, BAD, WEE1 | VCAM1 4558/4885DTYMK 732/4885POLB 3940/4885 |
| US-20070032455-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | NAPRT, NTPCR, PNP | VCAM1 957/4885DTYMK 1246/4885POLB 3572/4885 |
| US-10202408-B2 | Prodrugs and methods of use thereof | AKR1C3, AKR1C2, AKR1C1 | VCAM1 3751/4885DTYMK 304/4885POLB 1784/4885 |
| US-20100010094-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | NAPRT, NTPCR, QDPR | VCAM1 960/4885DTYMK 1141/4885POLB 3718/4885 |
| US-20170044191-A1 | Novel Prodrugs And Methods Of Use Thereof | AKR1C3, AKR1C2, AKR1B1 | VCAM1 3435/4885DTYMK 262/4885POLB 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.